CL2021002960A1 - Quelantes macrocíclicos y métodos de uso de los mismos. - Google Patents

Quelantes macrocíclicos y métodos de uso de los mismos.

Info

Publication number
CL2021002960A1
CL2021002960A1 CL2021002960A CL2021002960A CL2021002960A1 CL 2021002960 A1 CL2021002960 A1 CL 2021002960A1 CL 2021002960 A CL2021002960 A CL 2021002960A CL 2021002960 A CL2021002960 A CL 2021002960A CL 2021002960 A1 CL2021002960 A1 CL 2021002960A1
Authority
CL
Chile
Prior art keywords
radioimmunoconjugates
radiometal
methods
alpha
macrocyclic
Prior art date
Application number
CL2021002960A
Other languages
English (en)
Inventor
Wei Zhang
Rhys Salter
Vadim Dudkin
Fengbin Song
Shalom Goldberg
John Keith
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2021002960A1 publication Critical patent/CL2021002960A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan quelantes macrocíclicos (I) para la quelación de iones de radiometal emisores alfa, tales como actinio-225. También se proporcionan complejos de radiometal que contienen un ion de radiometal emisor alfa unido al quelante macrocíclico a través de enlace coordinado, y radioinmunoconjugados que contienen los complejos de radiometal unidos covalentemente a un ligando dirigido, tal como un anticuerpo o fragmento de unión al antígeno de este. Los radioinmunoconjugados pueden producirse mediante reacciones químicas clic. También se describen métodos para usar los radiocomplejos y radioinmunoconjugados para dirigirse selectivamente a células neoplásicas para radioterapia y para tratar enfermedades y trastornos neoplásicos.
CL2021002960A 2019-05-10 2021-11-09 Quelantes macrocíclicos y métodos de uso de los mismos. CL2021002960A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962846044P 2019-05-10 2019-05-10

Publications (1)

Publication Number Publication Date
CL2021002960A1 true CL2021002960A1 (es) 2022-06-24

Family

ID=70804855

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002960A CL2021002960A1 (es) 2019-05-10 2021-11-09 Quelantes macrocíclicos y métodos de uso de los mismos.

Country Status (20)

Country Link
US (2) US11576986B2 (es)
EP (1) EP3966211A1 (es)
JP (1) JP2022532157A (es)
KR (1) KR20220006613A (es)
CN (1) CN114127059A (es)
AU (1) AU2020273654A1 (es)
BR (1) BR112021022237A2 (es)
CA (1) CA3139806A1 (es)
CL (1) CL2021002960A1 (es)
CO (1) CO2021015713A2 (es)
CR (1) CR20210556A (es)
DO (1) DOP2021000233A (es)
EA (1) EA202193076A1 (es)
EC (1) ECSP21089217A (es)
IL (1) IL287909A (es)
MA (1) MA55885A (es)
MX (1) MX2021013667A (es)
PE (1) PE20220935A1 (es)
SG (1) SG11202112100PA (es)
WO (1) WO2020229974A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250240A1 (en) * 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
CA3200975A1 (en) * 2020-11-10 2022-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of use thereof
EP4284446A2 (en) 2021-01-27 2023-12-06 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
EP4317152A1 (en) * 2021-03-26 2024-02-07 Nihon Medi-Physics Co., Ltd. Compound, method for producing and method for storing compound, method for producing targeting agent, and composition
CA3215787A1 (en) * 2021-03-31 2022-10-06 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-egfr antibody, and radiopharmaceutical
AU2022282866A1 (en) 2021-05-27 2024-01-18 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
KR20240053674A (ko) * 2021-08-02 2024-04-24 레이즈바이오, 인크. 방사성 핵종의 안정화된 조성물 및 이의 용도
WO2023013589A1 (ja) * 2021-08-03 2023-02-09 住友化学株式会社 放射性金属錯体及びその製造方法、並びに放射性金属捕捉剤
CA3230156A1 (en) * 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma radioconjugates and uses thereof
PE20240727A1 (es) 2021-08-27 2024-04-15 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos
AU2022354706A1 (en) * 2021-09-29 2024-04-11 Olivia Newton-John Cancer Research Institute Macrocycle containing compounds and radiolabelled complexes thereof, as ligands in targeted radiotherapy applications
WO2023084396A1 (en) * 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
CN118302204A (zh) * 2021-11-09 2024-07-05 詹森生物科技公司 大环化合物及其诊断用途
WO2023144723A1 (en) 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用
CN114874214B (zh) * 2022-05-31 2023-03-21 南京航空航天大学 可偶联巯基的双功能大环螯合剂衍生物及其制备方法
CN114949259B (zh) * 2022-07-11 2023-09-19 重庆理工大学 一种氮杂冠醚结构的基因递送载体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8907507A (pt) * 1988-06-24 1991-06-11 Dow Chemical Co Quelante bifuncional macrociclico,seus complexos e seus conjugados com anticorpos
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
WO2015073746A2 (en) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases
LT3071595T (lt) 2013-11-19 2019-05-10 Fredax Ab Humanizuotas anti-kalikreino-2 antikūnas
JP2020515596A (ja) 2017-03-30 2020-05-28 コーネル ユニバーシティー α線放出放射線核種の大環状錯体およびがんの標的放射線療法におけるそれらの使用
CN117563022A (zh) * 2017-04-05 2024-02-20 康奈尔大学 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
JP2021502418A (ja) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
WO2019125982A1 (en) 2017-12-18 2019-06-27 Janssen Biotech, Inc. Radiolabeling of polypeptides
CN112513085B (zh) 2018-05-24 2024-06-18 詹森生物科技公司 Psma结合剂及其用途
SG11202104900SA (en) * 2018-11-20 2021-06-29 Univ Cornell Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer

Also Published As

Publication number Publication date
CN114127059A (zh) 2022-03-01
CA3139806A1 (en) 2020-11-19
CO2021015713A2 (es) 2021-11-30
MX2021013667A (es) 2022-01-31
WO2020229974A1 (en) 2020-11-19
MA55885A (fr) 2022-03-16
CR20210556A (es) 2021-12-17
AU2020273654A1 (en) 2021-11-25
ECSP21089217A (es) 2022-01-31
US20230110178A1 (en) 2023-04-13
US11576986B2 (en) 2023-02-14
IL287909A (en) 2022-01-01
PE20220935A1 (es) 2022-05-31
EP3966211A1 (en) 2022-03-16
BR112021022237A2 (pt) 2022-03-29
DOP2021000233A (es) 2022-07-31
US20200353105A1 (en) 2020-11-12
EA202193076A1 (ru) 2022-02-16
KR20220006613A (ko) 2022-01-17
SG11202112100PA (en) 2021-11-29
JP2022532157A (ja) 2022-07-13

Similar Documents

Publication Publication Date Title
CL2021002960A1 (es) Quelantes macrocíclicos y métodos de uso de los mismos.
NO20091379L (no) Effektiv syntese av chelatorer for nukleaer bildebehandling og radioterapi: blandinger og anvendelser
EA202090370A1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
CL2018002683A1 (es) Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata
BR112012020304A2 (pt) complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
EA201792522A1 (ru) Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
MY141119A (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
BRPI0512040A (pt) composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
BR112022007313A2 (pt) Conjugado de um agente quelante, e, radiofármaco
MX2022005821A (es) Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70.
CL2020003357A1 (es) Métodos para tratar el cáncer de pulmón con un antagonista de fijación al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
WO2022157094A3 (en) Lrrc15 antibodies and conjugates thereof
BR112022001045A2 (pt) Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit